About
Meg Krench joined Sanofi Ventures in 2021 with a background in biotech investing and business development. Previously, she worked as part of the External Innovation team at Vertex Pharmaceuticals and at RA Capital, a crossover investment fund. Meg currently serves as a director for Normunity and as an observer for several companies including Draig Therapeutics, Eligo Bioscience, Korsana Biosciences, Quralis, and a stealth immunology company. Meg also supported Sanofi Ventures’ investment in Aliada Therapeutics before its acquisition by Abbvie for $1.4 billion. Meg holds a Ph.D. in Neuroscience from Massachusetts Institute of Technology and a B.S. with Honors in Neuroscience from The Pennsylvania State University. She is also co-chair of the Board of Directors for the New England Venture Network.
Sign up to see Meg Krench's full profile
Access investment thesis, focus areas, bio, and contact details for Meg Krench and 22,000+ other VC professionals.